Proguanil
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Atazanavir Proguanil 853 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potentially compromised antimalarial activity |
Not reported |
100 mg with 250 mg atovaquone x 1 | Proguanil AUC decreased 41%, Cmax no significant change |
If coadministering monitor for anti-malarial efficacy |
| Efavirenz Proguanil 494 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | 100 mg with 250 mg atovaquone x 1 | Proguanil AUC decreased 43%; Cmax no significant change |
Consider using alternative agents. If coadministering, dose adjustment not established |
||
| Efavirenz Proguanil 493 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential decreased antimalarial effects |
300 mg x 1 | Proguanil AUC increased 113%; Cmax increased 47%; Cycloguanil AUC decreased 38%; Cmax decreased 31% |
Consider using alternative agents. If coadministering, dose adjustment not established |

